On the stock market since 2023, it operates in the world of health and science. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
An average decline of 6% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: Right now the product sells for less than it costs to make; every sale deepens the loss.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Sales run at $11.4M a year. A small number, but proof the product has real buyers.
A loss of $3.3M against $11.4M in annual sales.
The stock sits at $0.0000. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 8.5 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, NUTTQ sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: NUTTQ is a high-risk stock — not yet profitable, and its future rides on its product catching on.